← Eichor
Study identifier: NCT07027020 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction

Condition: Spina Bifida  ·  Sponsor: Central Hospital, Nancy, France

PhasePhase 3
Planned participants60
Who can joinAll sexes, 6 Years to 17 Years
Healthy volunteersNo

About this study

Malformation of the lumbosacral region (spina bifida) affects the innervation of the bladder in children. The usual evolution leads to a neurological bladder with small capacity, poor compliancy and overactivity, exposing to incontinence and obstruction to the evacuation of urine. It is responsible for renal failure requiring dialysis and transplantation. Current therapeutics aim to evacuate urine and reduce intravesical pressure. It gradually combines 1) intermittent catheterization, 2) anticholinergics, 3) botulinum toxin (Botox®) injection into the detrusor (bladder muscle) by cystoscopy and 4) surgery (vesicostomy, Bricker, enterocystoplasty). Oxybutynin relaxes the detrusor, improves continence and reduces intravesical pressure. It is usually administered per os, but there are contraindications (glaucoma, myasthenia), side effects (constipation, dry mouth). It can be difficult to swallow for children, and drug resistance may develop. It can lead to ineffective treatment requiring therapeutic escalation. The next step, intradetrusor Botox® injection, is invasive (cystoscopy), has a limited duration of action (6 months) and must be performed under general anesthesia in children. Surgical treatments are effective but irreversible and responsible for morbidity and mortality. A randomized study was performed demonstrating the efficacy of intravesical oxybutynin compared to oral administration in adult patients. This study found a significant increase in bladder capacity and …

This description comes directly from the study's public registry record.

Talk to the study team

Nicolas BERTE, Dr  ·  0383155287  ·  n.berte@chru-nancy.fr

Jean-Louis LEMELLE, Pr  ·  0383154729  ·  jl.lemelle@chru-nancy.fr

Always discuss trial participation with your own doctor first.

Locations (19)

Centre Hospitalier Universitaire de BesançonBesançon, FranceNot Yet Recruiting
Centre Hospitalier Universitaire De BordeauxBordeaux, FranceNot Yet Recruiting
Centre Hospitalier Régional Et Universitaire De BrestBrest, FranceNot Yet Recruiting
Centre Hospitalier Universitaire De Caen NormandieCaen, FranceNot Yet Recruiting
Centre Hospitalier Universitaire de Clermont-FerrandClermont-Ferrand, FranceNot Yet Recruiting
Centre Hospitalier De ColmarColmar, FranceNot Yet Recruiting
Centre Hospitalier Universitaire Grenoble AlpesGrenoble, FranceNot Yet Recruiting
Centre Hospitalier Universitaire de LilleLille, FranceNot Yet Recruiting
Centre Hospitalier Et Universitaire De LimogesLimoges, FranceNot Yet Recruiting
Centre Hospitalier Régional De MarseilleMarseille, FranceNot Yet Recruiting
Fondation Lenval NiceNice, FranceNot Yet Recruiting
Hôpital Necker Enfants MaladesParis, FranceNot Yet Recruiting

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07027020